MX2016000385A - Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. - Google Patents
Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.Info
- Publication number
- MX2016000385A MX2016000385A MX2016000385A MX2016000385A MX2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A
- Authority
- MX
- Mexico
- Prior art keywords
- vegf antagonist
- prematurity
- infant
- antagonist
- treating retinopathy
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 title abstract 3
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00821—Methods or devices for eye surgery using laser for coagulation
- A61F9/00823—Laser features or special beam parameters therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845073P | 2013-07-11 | 2013-07-11 | |
| PCT/IB2014/063003 WO2015004626A2 (en) | 2013-07-11 | 2014-07-10 | Use of a vegf antagonist in treating retinopathy of prematurity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016000385A true MX2016000385A (es) | 2016-04-29 |
Family
ID=51211284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000385A MX2016000385A (es) | 2013-07-11 | 2014-07-10 | Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20160159893A1 (enExample) |
| EP (1) | EP3019527A2 (enExample) |
| JP (1) | JP2016523956A (enExample) |
| KR (1) | KR20160030504A (enExample) |
| CN (1) | CN105377890A (enExample) |
| AR (1) | AR096893A1 (enExample) |
| AU (3) | AU2014288847A1 (enExample) |
| BR (1) | BR112016000282A2 (enExample) |
| CA (1) | CA2917813A1 (enExample) |
| HK (1) | HK1221231A1 (enExample) |
| MX (1) | MX2016000385A (enExample) |
| RU (1) | RU2676303C2 (enExample) |
| TW (1) | TW201536317A (enExample) |
| WO (1) | WO2015004626A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3252079B8 (en) | 2006-04-07 | 2020-09-09 | Aerpio Therapeutics LLC | Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| PL2451279T3 (pl) | 2009-07-06 | 2019-09-30 | Aerpio Therapeutics, Inc. | Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| CN108697772B (zh) | 2015-12-30 | 2022-06-24 | 马歇尔大学科研协会 | 用于治疗视网膜病的组合物和方法 |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| WO2020223209A1 (en) | 2019-04-29 | 2020-11-05 | Aerpio Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003273299B2 (en) * | 2002-09-05 | 2010-04-01 | Medimmune, Llc | Methods of preventing or treating cell malignancies by administering CD2 antagonists |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| PL1660057T3 (pl) * | 2003-08-27 | 2012-10-31 | Ophthotech Corp | Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| AU2006236439B2 (en) * | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2007038453A2 (en) * | 2005-09-26 | 2007-04-05 | Advanced Ocular Systems Limited | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| KR20210056449A (ko) * | 2007-11-07 | 2021-05-18 | 안트로제네시스 코포레이션 | 조산 합병증의 치료에 있어서의 제대혈의 용도 |
| WO2010045506A2 (en) * | 2008-10-16 | 2010-04-22 | Kathleen Cogan Farinas | Sustained drug delivery system |
| RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
| EP3165606A1 (en) * | 2009-05-01 | 2017-05-10 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
| US20140249191A1 (en) * | 2011-10-20 | 2014-09-04 | Avienne Pharmaceuticals Gmbh | Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases |
| PL2887958T3 (pl) * | 2012-08-21 | 2021-11-22 | Opko Pharmaceuticals, Llc | Formulacje liposomowe |
-
2014
- 2014-07-10 US US14/903,435 patent/US20160159893A1/en not_active Abandoned
- 2014-07-10 EP EP14741408.0A patent/EP3019527A2/en not_active Withdrawn
- 2014-07-10 AU AU2014288847A patent/AU2014288847A1/en not_active Abandoned
- 2014-07-10 CN CN201480039605.XA patent/CN105377890A/zh active Pending
- 2014-07-10 TW TW103123847A patent/TW201536317A/zh unknown
- 2014-07-10 HK HK16109250.8A patent/HK1221231A1/zh unknown
- 2014-07-10 JP JP2016524933A patent/JP2016523956A/ja active Pending
- 2014-07-10 BR BR112016000282A patent/BR112016000282A2/pt not_active IP Right Cessation
- 2014-07-10 RU RU2016104398A patent/RU2676303C2/ru not_active IP Right Cessation
- 2014-07-10 MX MX2016000385A patent/MX2016000385A/es unknown
- 2014-07-10 KR KR1020167000259A patent/KR20160030504A/ko not_active Ceased
- 2014-07-10 WO PCT/IB2014/063003 patent/WO2015004626A2/en not_active Ceased
- 2014-07-10 CA CA2917813A patent/CA2917813A1/en not_active Abandoned
- 2014-07-11 AR ARP140102578A patent/AR096893A1/es unknown
-
2017
- 2017-06-26 AU AU2017204326A patent/AU2017204326A1/en not_active Abandoned
-
2019
- 2019-07-16 AU AU2019206000A patent/AU2019206000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014288847A1 (en) | 2016-01-28 |
| EP3019527A2 (en) | 2016-05-18 |
| HK1221231A1 (zh) | 2017-05-26 |
| RU2016104398A3 (enExample) | 2018-05-31 |
| WO2015004626A3 (en) | 2015-05-28 |
| WO2015004626A2 (en) | 2015-01-15 |
| TW201536317A (zh) | 2015-10-01 |
| RU2676303C2 (ru) | 2018-12-27 |
| AU2019206000A1 (en) | 2019-08-01 |
| BR112016000282A2 (pt) | 2017-12-12 |
| AR096893A1 (es) | 2016-02-03 |
| AU2017204326A1 (en) | 2017-07-13 |
| JP2016523956A (ja) | 2016-08-12 |
| RU2016104398A (ru) | 2017-08-16 |
| KR20160030504A (ko) | 2016-03-18 |
| CN105377890A (zh) | 2016-03-02 |
| CA2917813A1 (en) | 2015-01-15 |
| US20160159893A1 (en) | 2016-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016000385A (es) | Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. | |
| MX2016000384A (es) | Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| PH12018501325A1 (en) | Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion | |
| BR112018069789A2 (pt) | medicamento obtido pela combinação do agonista de fxr e arb | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| SG10201903112WA (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| BR112017024509A2 (pt) | tratamento de doença do cns com células de plexo coroide induzíveis encapsulada | |
| NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2017004658A (es) | Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno de almacenamiento lipidico. | |
| PH12017500098A1 (en) | Suspension compositions of cyclosporin a for subconjunctival and periocular injection | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| Fareed et al. | Psychoimmunomodulatory activity of Salvadora persica L.(Miswak) extract on stress model in rats | |
| WO2014144731A3 (en) | Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same | |
| Committee on Child Health Financing | Guiding principles for managed care arrangements for the health care of newborns, infants, children, adolescents, and young adults | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares | |
| Van Der Meer | Hyperammonaemic encephalopathy in a child: case report | |
| Kathirvel | Thrombocytopenia: case report | |
| 王扬 | How A Dog’s 9 Babies Came To Be Called | |
| Sedani | Hypersensitivity: case report | |
| Pratini | Baclofen/lorazepam |